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anti-malarial therapy in Tororo, Uganda
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Jordan Tappero3, Philip J Rosenthal1, Frank Kaharuza4, Moses R Kamya5 and Grant Dorsey1
Abstract
Background: The burden of malaria has decreased in parts of Africa following the scaling up of control
interventions. However, similar data are limited from high transmission settings.
Methods: A cohort of 100 children, aged six weeks to 10 months of age, were enrolled in an area of high malaria
transmission intensity and followed through 48 months of age. Children were given a long-lasting insecticide-
treated bed net (LLIN) at enrolment and received all care, including monthly blood smears and treatment with
artemisinin-based combination therapy (ACT) for uncomplicated malaria, at a dedicated clinic. The incidence of
malaria was estimated by passive surveillance and associations between malaria incidence and age, calendar time
and season were measured using generalized estimating equations.
Results: Reported compliance with LLINs was 98% based on monthly routine evaluations. A total of 1,633 episodes
of malaria were observed, with a median incidence of 5.3 per person-year (PPY). There were only six cases of
complicated malaria, all single convulsions. Malaria incidence peaked at 6.5 PPY at 23 months of age before
declining to 3.5 PPY at 48 months. After adjusting for age and season, the risk of malaria increased by 52% from
2008 to 2011 (RR 1.52, 95% CI 1.10-2.09). Asymptomatic parasitaemia was uncommon (monthly prevalence <10%)
and rarely observed prior to 24 months of age.
Conclusions: In Tororo, despite provision of LLINs and prompt treatment with ACT, the incidence of malaria is very
high and appears to be rising. Additional malaria control interventions in high transmission settings are likely needed.
Trial registration: Current Controlled Trials Identifier NCT00527800
Keywords: Malaria, Plasmodium falciparum, Immunity, Epidemiology
Background
Malaria causes more than 500 million clinical cases and is
responsible for about one million deaths annually, mostly
among African infants and young children [1]. Uganda
bears a particularly large burden, having among the highest
rates of transmission worldwide [2]. Within Uganda, there
is significant heterogeneity of malaria transmission. In the
most recent malaria indicator survey, from 2009, parasite
prevalence among children under five years of age ranged
from <5% in urban centres to >60% in rural settings [3].
As utilization of malaria control interventions, includ-
ing long-lasting insecticide treated bed nets (LLINs), in-
door residual spraying of insecticides, and prompt
treatment with artemisinin-based combination therapy
(ACT) has increased, many reports have shown a sub-
stantial drop in malaria transmission, malaria-associated
hospitalizations, and malaria-associated deaths [1,4-8].
However, these findings have not been uniform across
Africa [5,9,10]. One recent study showed a lack of de-
cline in slide positivity rates and admissions for cerebral
malaria from 2001–2010 in Malawi, and another showed
an increase in malaria-related hospitalizations over a
similar time period in Uganda [9,11]. These, and many
other relevant recent studies, were retrospective in
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design, and so unable to provide reliable estimates of
malaria incidence.
Considerable knowledge regarding the natural history
of malaria, acquisition of anti-malarial immunity, and
impact of interventions has been gained from longitu-
dinal cohort studies. Beginning with Koch’s seminal
studies in Papua New Guinea in the late 1800s, these
studies have consistently revealed that, in endemic popu-
lations, the incidence and severity of malaria decreases
considerably after the first years of life, with a corre-
sponding rise in the prevalence of asymptomatic carriage
of parasites [12-15]. Although widespread use of LLINs
and ACT have been associated with declines in the inci-
dence of malaria in many regions, there have been con-
cerns over how decreasing exposure to malaria parasites
may alter the natural history of disease, and possibly
delay the acquisition of anti-malarial immunity [5,10,15].
To better understand the impact of LLINs and ACT on
the natural history of malaria in a high endemicity set-
ting, the incidence of malaria and prevalence of asymp-
tomatic parasitaemia were evaluated in a cohort of
children living in Tororo, Uganda.
Methods
Study site and participants
The Tororo Child Cohort (TCC) study was conducted in
Tororo, a rural district in south-eastern Uganda with an
entomological inoculation rate (EIR) estimated at 562 in-
fective bites per person year (PPY) in 2002 [16]. Details
of this study have been described elsewhere [17-20].
Briefly, convenience sampling was used to enroll chil-
dren referred to a dedicated study clinic from an adja-
cent post-natal clinic at Tororo District Hospital. The
sub-study described in this report included only children
born to HIV-uninfected mothers who met the following
enrolment criteria: 1) age six weeks to <10 months, 2)
agreement to come to the study clinic for any febrile epi-
sode or other illness, 3) residence within a 30 km radius
of the clinic, 4) absence of an active medical problem re-
quiring in-patient evaluation at screening, and, 5)
provision of informed consent. At enrolment, all study
participants received an LLIN (Permanet).
Follow-up of study participants
Subjects were followed for all medical problems at a
dedicated study clinic open seven days a week, and par-
ents/guardians were encouraged to bring their children
to the clinic whenever they were ill. After hours, care
was available through the adjacent hospital paediatric
ward. Children presenting with new medical problems
underwent a standardized medical evaluation using algo-
rithms to guide therapy for illnesses. Medications with
anti-malarial activity were avoided for the treatment of
non-malarial illnesses. Monthly assessments were done
in the study clinic to ensure compliance with study pro-
tocols, measure adherence to LLINs through recall of
LLIN use in the prior evening, and perform routine
blood smears. Study participants were withdrawn for: 1)
movement out of the study area, 2) inability to be
located for >60 consecutive days, 3) withdrawal of
informed consent, 4) inability to adhere to the study
schedule and procedures, or, 5) inability to tolerate the
drugs used for malaria treatment.
Malaria diagnosis and management
Subjects who presented with a documented fever (tym-
panic temperature ≥38.0°C) or history of fever in the
previous 24 hours had blood obtained by finger prick for
a thick smear. If the thick smear was positive for malaria
parasites, the patient was diagnosed with malaria regard-
less of parasite density. At the time of their first episode
of uncomplicated malaria, study participants ≥4 months
and ≥5 kg were randomly assigned to receive open-label
artemether-lumefantrine (AL) or dihydroartemisinin-
piperaquine (DP). Each first daily dose of study drugs
was directly observed at the study clinic. Study partici-
pants received the assigned treatment for all subsequent
episodes of uncomplicated malaria. Episodes of uncom-
plicated malaria in children less than four months of age
or weighing <5 kg as well as episodes of complicated
malaria were treated with quinine. Clinical treatment
failures occurring within 14 days of initiation of therapy
for uncomplicated malaria were treated with quinine.
Those occurring within 14 days of initiation of therapy
with quinine were treated with quinine plus clindamycin.
All children with malaria were followed up on days 1, 2,
3, 7, 14, 21, and 28 following diagnosis. Thick blood
smears were collected on all malaria follow-up days
apart from day 1 [20].
Laboratory methods
Thick blood smears were stained with 2% Giemsa for 30
min. Parasite densities were calculated from thick
smears by counting the number of asexual parasites per
200 leukocytes (or per 500 leukocytes, if the count was
<10 asexual parasites/200 leukocytes), assuming a
leukocyte count of 8,000/μl. A blood smear was consid-
ered negative when the examination of 100 high power
fields did not reveal asexual parasites. For quality con-
trol, all slides were read by a second reader, and discrep-
ancies were settled by a third reader. Laboratory
technicians were blinded to the study participants’ treat-
ment assignments.
Statistical methods
Data were double entered into an Access database. Data
analysis was done using Stata version 11 (Stata Corp,
College Station, TX, USA). The observation period
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began one day after enrolment and ended when the
child turned four years of age or on the day the child
was prematurely withdrawn from the study.
Incident episodes of malaria were defined as all treat-
ments not preceded by another treatment in the prior 14
days. The incidence of malaria was calculated as the num-
ber of episodes per person years at risk. Asymptomatic
parasitaemia was defined as a positive routine blood smear
in the absence of fever that was not followed by the diagno-
sis of malaria in the subsequent seven days. As asymptom-
atic parasitaemia was assessed using active surveillance, the
monthly prevalence of asymptomatic parasitaemia was
ascertained for each month of observation. Geometric
mean parasite densities were calculated for symptomatic
malaria and asymptomatic parasitaemia.
Generalized additive regression with smoothing splines
were used to visualize the effects of age, calendar time,
and season on the incidence of malaria and prevalence of
asymptomatic parasitaemia [21]. Inference was obtained
using bootstrapping at the level of an individual with
1,000 replicates. The relative risk of incident malaria and
prevalent asymptomatic parasitaemia by age, calendar
time and season was calculated using generalized estimat-
ing equations with robust standard errors [22].
Ethical approval
Informed consent was obtained from the parent or guard-
ian of all study participants. The study protocol was
approved by the Uganda National Council of Science and
Technology and the institutional review boards of the
University of California, San Francisco, Makerere Univer-
sity and the Centers for Disease Control and Prevention.
Results
Study profile and descriptive statistics
A total of 100 children aged between six weeks and <10
months of age (median 5.5 months) were enrolled between
August 2007 and January 2008. Children were followed for
a median of 3.5 years. Of 100 children enrolled, 96 were
followed through one year of age, 88 through two years of
age, 83 through three years of age, and 79 through four
years of age. Children were prematurely withdrawn for the
following reasons: 13 moved out of the study area, three
were unable to comply with study procedures, two with-
drew consent, one had treatment failure following quinine
+ clindamycin, one was unable to be re-administered study
drugs due to drug toxicity, and one died. At the time of
monthly routine assessment, 98% of study participants
were reported to have slept under an LLIN the prior even-
ing (Table 1).
Treatments for malaria
A total of 1,633 incident cases of malaria were observed.
Only six of 1,633 (0.4%) incident cases were complicated
(all so-classified based on a single convulsion). There were
12 treatment failures within 14 days of treatment: five
early treatment failures associated with complicated mal-
aria following treatment with AL due to single convulsions
(two) or severe anaemia (three, all in same child); two epi-
sodes of recurrent malaria 14 days after treatment with
AL; and five treatments with quinine + clindamycin fol-
lowing treatment with quinine. The only death occurred
at home in a 35-month-old boy one day after he was diag-
nosed with his 27th incident episode of malaria. Of note,
this child had three prior episodes of severe anaemia two
days following initiation of treatment with AL, represent-
ing the only episodes meeting criteria for severe malaria in
the entire cohort. Considering parasite clearance, 94.9%
and 99.8% of patients had a negative blood smear two and
three days following initiation of therapy, respectively.
Malaria incidence
The median incidence of malaria was 5.4 episodes PPY
(Table 1), with 25% of children having an incidence >7
Table 1 Descriptive statistics of study cohort
Characteristic Findings
Number of children enrolled 100
Median age at enrolment in months (range) 5.52 (1.50-9.93)
Female, n (%) 40 (40%)
Rural residence, n (%) 76 (76%)
Number of children who reached four years of age, n (%) 79 (79%)
Median years of follow-up (IQR) 3.46 (3.24-3.66)
Proportion who reported sleeping under an LLIN* (%) 3,934/4,008 (98%)
Antimalarial group children were randomized to, n (%)
DP 51 (51%)
AL 42 (42%)
Never randomized 7 (7%)
Total incident episodes of malaria** 1,633
Uncomplicated malaria treated with DP 847
Uncomplicated malaria treated with AL 778
Uncomplicated malaria treated with quinine for
age <4 months
2
Quinine for complicated malaria 6
Treatments for malaria within 14 days of prior episode 12
Quinine for early treatment failure following AL 5
Quinine for recurrent malaria on day 14 following AL 2
Quinine/clindamycin for early treatment failure
following quinine
3
Quinine/clindamycin for recurrent malaria days 4–14
following quinine
2
Median malaria incidence through four years of age per
person years (IQR)
5.44 (3.18-7.00)
Total episodes of asymptomatic parasitaemia 186
Monthly prevalence of asymptomatic parasitaemia 5.0%
Note: IQR, interquartile range; LLIN, long-lasting insecticide treated bed net;
DP, dihydroartemisinin-piperaquine; AL, artemether-lumefantrine.
* Assessed at the time of monthly routine visits to the clinic.
** All treatments for malaria not proceed by another treatment in the prior 14 days.
Jagannathan et al. Malaria Journal 2012, 11:435 Page 3 of 8
http://www.malariajournal.com/content/11/1/435
episodes PPY. Only five children were never diagnosed
with malaria and four of these were followed for <6
months. The incidence of malaria was high throughout
the year, with two mild seasonal peaks (Figure 1). After
adjusting for age and calendar year, the risk of malaria was
28% higher from Nov-Jan (95% CI 14-43%, P < 0.001) and
26% higher from Apr-Jul (95% CI 14-40%, P < 0.001) com-
pared to the incidence from Aug-Oct (Table 2). The inci-
dence of malaria increased with time over the four years
of observation (Figure 2). After adjusting for age and sea-
sonality, the risk of malaria was 52% higher in 2011 com-
pared to 2008 (95% CI 10-109%, P = 0.01, Table 2). The
incidence of malaria was stable from 10 to <30 months of
age, then gradually decreased from 30 to 48 months of age
(Figure 3). After adjusting for calendar year and seasonal-
ity, the incidence of malaria was 36% lower in children 42
to <48 months of age compared to those 10 to <18
months of age (95% CI 14-52%, P = 0.003).
Asymptomatic parasitaemia
Of 6,951 blood smears obtained outside of the first 14
days of malaria follow-up, 475 demonstrated parasit-
aemia in children without fever. Of these, 186 met the
specified definition of asymptomatic parasitaemia, as
289 were followed by malaria within seven days. Overall,
the monthly prevalence of asymptomatic parasitaemia
was 5.0% (Table 1.) Asymptomatic parasitaemia was un-
common throughout the study, peaking at ~9% at 39
months of age (Figure 4). The monthly risk of asymp-
tomatic parasitaemia was significantly higher in children
36 to <48 months of age (8.3%) compared to those 10
to <18 months of age (2.5%) (RR 4.4, 95% CI 2.6-7.5,
P < 0.001). Significant heterogeneity in the prevalence of
asymptomatic parasitaemia was observed, with 10% of
children having nearly 55% of the total episodes and 45%
of children having no episodes of asymptomatic parasit-
aemia during follow-up (P < 0.001 overdispersed com-
pared with Poisson). Asymptomatic parasitaemia was
more common in children with the most malaria; all
children having more than 10 episodes of asymptomatic
parasitaemia were in the highest quartile of incident
malaria, and only one child with less than two episodes
of malaria per year had an episode of asymptomatic
parasitaemia.
Figure 1 Predictors of malaria incidence - Malaria incidence by
season. Predictors of malaria incidence visualized using a generalized
additive regression model with smoothing splines. The model included
season, calendar date, and age. Standard errors are indicated by
shaded areas and were generated by bootstrapping with 1,000
replicates. Absolute incidence values for each of the three variables
were calculated using median values for the other two variables.
Table 2 Factors associated with malaria incidence
Risk factor Categories Relative Risk* (95% CI) p-value
Season August-October 1.0 (reference) -
February-March 1.03 (0.92-1.16) 0.56
November-January 1.28 (1.14-1.43) <0.001
April-July 1.26 (1.14-1.40) <0.001
Year 2008 1.0 (reference) -
2009 1.15 (0.97-1.36) 0.10
2010 1.42 (1.11-1.82) 0.005
2011 1.52 (1.10-2.09) 0.01
Age 10- < 18 months 1.0 (reference) -
18- < 24 months 1.05 (0.92-1.19) 0.48
24- < 30 months 1.09 (0.91-1.30) 0.34
30- < 36 months 0.97 (0.79-1.19) 0.77
36- < 42 months 0.78 (0.61-1.00) 0.05
42- < 48 months 0.64 (0.48-0.86) 0.003
Note: CI, confidence interval.
Figure 2 Predictors of malaria incidence - Malaria incidence by
calendar date. Predictors of malaria incidence visualized using a
generalized additive regression model with smoothing splines
(see details Figure 1).
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Effect of age on parasite density
The geometric mean parasite density was assessed by
six-month age increments, stratified by symptomatic
malaria and asymptomatic parasitaemia. The geometric
mean parasite density was significantly higher during
malaria episodes than during episodes of asymptoma-
tic parasitaemia (22,200/μL vs 1,900/μL, respectively;
P < 0.0001). There was no significant trend for parasite
densities for either malaria or asymptomatic parasit-
aemia over age (Table 3).
Discussion
In this longitudinal cohort of 100 children given LLINs
and ACT and residing in an area of known high trans-
mission intensity in eastern Uganda, a remarkably high
incidence of malaria was observed, peaking at 6.5 epi-
sodes per child per year at 25 months of age. Import-
antly, the vast majority (99.7%) of malaria cases were
uncomplicated. The incidence declined as children
reached three years of age, suggesting the development
of natural immunity to malaria [23], although children
on average still had four episodes per year at four years
of age, and asymptomatic parasitaemia, a finding typic-
ally associated with anti-malarial immunity, was
observed in less than 10% of individuals. Perhaps most
concerning, in the setting of near universal use of LLINs
to limit mosquito exposure and ACT to effectively treat
malaria, the incidence of malaria was very high through-
out this study and rose 52% from 2008 through 2011.
Many reports across Africa have shown significant
declines in malaria-related deaths and hospitalizations
over the past decade, and it is routinely suggested that
malaria-control interventions - including usage of LLINs
and ACT - are responsible for these declines [4-8]. How-
ever, few of these studies were done with longitudinal
cohorts in high-endemicity settings. Contrasting with
many reports, this study and recent reports from
Malawi, Uganda, and Senegal showed a lack of decline
in malaria incidence [5,9,10].
The reason for a lack of decline, and indeed a signifi-
cant increase in the incidence of malaria in Tororo is
unknown. The increase may be due to changes in drug
resistance, vector species, insecticide resistance, and/or
climate/rainfall, leading to increases in exposure to mal-
aria vectors. Considering drugs, AL and DP have both
shown outstanding efficacy in numerous recent studies,
and there is no convincing evidence of resistance to
these agents in Africa. Although we did not collect
detailed information on mosquito species or biting
habits, preliminary data from the East African Inter-
national Centers of Excellence in Malaria Research
(ICEMR) estimates the EIR in Tororo to be 379 infective
bites PPY (unpublished data from CDC light traps col-
lected between Oct 2011 and Sep 2012), near the EIR of
562 infective bites PPY estimated by human landing
catches in 2002 [16]. The majority of mosquitoes col-
lected during this period were Anopheles gambiae com-
plex (93.5%), as found in 2002 [16]. Notably, population
based surveys in this area have revealed significant
increases in LLIN coverage in Tororo over the past six
years, with the proportion of children <5 years of age
sleeping under a LLIN increasing from 13% in 2006 [24]
to 42% in 2009 [25] and 62% in 2012 (East African
ICEMR, unpublished). However, several recent reports
have also shown increasing resistance of anopheline
mosquitoes to pyrethroid insecticides in Tororo. Preva-
lence of the knockdown resistance (KDR) L1014S muta-
tion has increased from 29% in 2002 to 75% in 2008 in
mosquitoes collected from Tororo [26,27], suggesting
Figure 3 Predictors of malaria incidence - Malaria incidence by
age. Predictors of malaria incidence visualized using a generalized
additive regression model with smoothing splines (see details Figure 1).
Figure 4 Prevalence of asymptomatic parasitaemia. Prevalence
of asymptomatic parasitaemia by age modelled by generalized
additive regression. Standard error is indicated by the shaded area
and was generated by bootstrapping with 1,000 replicates.
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that the effectiveness of LLINs may be waning in this
area, as also seen in other parts of Africa [10,28]. In
these settings, additional control measures - including
indoor residual spraying [29], larvicides and other vector
control measures [30], and chemoprevention [31], will
be required.
Importantly, even though more than 1,600 cases of
malaria were diagnosed in the 100 children enrolled in
this cohort, remarkably few cases of malaria were asso-
ciated with complications. Only six episodes met criteria
for complicated malaria, and all these cases were due to
a single convulsion (danger sign) and did not meet cri-
teria for severe malaria. There were no cases of cerebral
malaria or respiratory distress. This result is in sharp
contrast to historical reports suggesting that 2% of all
clinical attacks of malaria are severe [32]. Consistent
with earlier observations from a cohort study in Uganda
conducted in a lower transmission setting [33,34], these
findings suggest that malaria-related morbidity can be
greatly limited with prompt access to appropriate diag-
nosis and highly effective treatment. Early treatment fail-
ures were also exceedingly rare, consistent with prior
findings that ACT is very efficacious [35-38]. Of 12
treatment failures within 14 days of prior therapy, there
were three cases of severe anaemia, all in the same child.
The unfortunate death of this two-year old boy, who had
had 27 prior episodes of malaria, is clear evidence that,
even with prompt diagnosis and therapy, malaria
remains a dangerous disease in need of improved con-
trol measures.
As others have reported, children in this cohort
appeared to acquire anti-disease immunity as they aged.
The incidence of malaria declined in children after
30–36 months of age, and asymptomatic parasitaemia
was more common in older children [23]. However,
given the degree of exposure and high incidence in the
cohort, the natural acquisition of anti-malarial immunity
in this cohort was remarkably slow. A surprising finding
was the low prevalence of asymptomatic parasitaemia in
this cohort - 5% based on monthly microscopy. In con-
trast, parasite prevalence rates from eastern Uganda in
the 2009 malaria indicator survey were nearly 40% in
children <5 [25], and in a similarly aged cohort from
Kampala, Uganda, a lower transmission setting, the
prevalence of asymptomatic parasitaemia was much
higher (17%) [39]. Given a lack of standard diagnostic
criteria, asymptomatic parasitaemia described in this re-
port accounted for whether or not children were in a
pre-symptomatic period, excluding any child that devel-
oped malaria within seven days [40]. Although varying
definitions may explain some of these differences, the
significantly low prevalence of asymptomatic infection
observed here suggests that prompt and repeated treat-
ments with highly effective ACT may alter the acquisi-
tion of anti-parasite immunity, limiting infections to
symptomatic disease in young children. Further studies
addressing the impact of ACT on the development of
anti-malarial immunity are needed.
There were several limitations to this study. The co-
hort was enrolled by convenience sampling, limiting the
generalizability of the findings. Although the analysis
attempted to adjust for calendar time, children enrolled
early in the study may have differed from those enrolled
later. Detailed information was also unavailable regard-
ing individual- and household-level exposure. A further
limitation was the assessment for LLIN use by self-report,
and not by directly observed LLIN usage, which may have
overestimated LLIN coverage [41]. Finally, children
received treatment for malaria if they presented with
fever and any parasitaemia. If non-malarial causes of
fever were the aetiology of some of these presenta-
tions, malaria incidence may have been overestimated
in this cohort. However, the geometric mean parasite
densities of malaria episodes were significantly higher
than those of episodes of asymptomatic parasitaemia,
suggesting that malaria contributed to symptoms in
most cases where anti-malarial therapy was given.
Conclusions
In conclusion, despite reports of decreasing malaria mor-
bidity and mortality across many parts of Africa, the inci-
dence of malaria continues to be very high in Tororo,
Uganda, even in a setting with LLINs and ACT, and this
incidence appears to be rising. Thus, additional malaria
control interventions among young children living in high
transmission settings are needed. Fortunately, with
prompt diagnosis and effective treatment, malaria-related
complications can be limited even in high transmission
settings.
Table 3 Geometric mean parasite densities (GMPD) by age and clinical manifestation
Clinical manifestation Asexual parasites/μL stratified by age in months p-
value*
All
ages
p-
value**10- < 18 18- < 24 24- < 30 30- < 36 36- < 42 42- < 48
Symptomatic malaria 20916 24177 20912 24631 20329 22813 .938 22216 ref
Asymptomatic parasitaemia 1545 1336 2018 1948 2010 1928 .905 1901 <0.001
* Comparisons between log-transformed parasite densities by age groups using generalized estimating equations.
** Comparison between GMPD of malaria vs asymptomatic parasitaemia using generalized estimating equation.
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